We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04053543
Recruitment Status : Terminated (LOE)
First Posted : August 12, 2019
Last Update Posted : August 26, 2020
Medpace, Inc.
Innovative Analytics
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Information provided by (Responsible Party):
Complexa, Inc.

Tracking Information
First Submitted Date  ICMJE July 19, 2019
First Posted Date  ICMJE August 12, 2019
Last Update Posted Date August 26, 2020
Actual Study Start Date  ICMJE August 9, 2019
Actual Primary Completion Date August 12, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 8, 2019)
  • Incidence of AEs [ Time Frame: 6 months ]
    Adverse events occurring during the treatment period
  • Changes in respiration [ Time Frame: 6 months ]
    Change from baseline values at each post-baseline time point
  • Changes in heart rate [ Time Frame: 6 months ]
    Change from baseline values at each post-baseline time point
  • Changes in blood pressure [ Time Frame: 6 months ]
    Change from baseline values at each post-baseline time point
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 8, 2019)
  • PAH-specific medication changes [ Time Frame: 6 months ]
    Addition or removal of PAH-specific medications, including any dose changes
  • 6 Minute Walk Distance [ Time Frame: 6 months ]
    Change from baseline in 6-minute walk distance (6MWD)
  • Who Classification of Functional Status [ Time Frame: 6 months ]
    Change from baseline in WHO Classification of Functional Status of Patients with PH
  • Clinical worsening [ Time Frame: 6 months ]
    Death from any cause, hospitalization for worsening PAH, Disease progression, unsatisfactory long-term clinical response
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE CXA-10 Study in Subjects With Pulmonary Arterial Hypertension
Official Title  ICMJE A Phase 2, Multi-Center, Open-Label Study to Evaluate Long-term Safety and Efficacy of CXA-10 in Subjects With Pulmonary Arterial Hypertension on Stable Background Therapy: Extension to Study CXA-10-301
Brief Summary This is a Phase 2, multicenter, open-label extension (OLE) of study CXA-10-301, to evaluate the long term safety and efficacy of daily dosing of CXA-10.
Detailed Description

This is a Phase 2, multicenter, open-label extension (OLE) of study CXA-10-301, to evaluate the long term safety and efficacy of daily dosing of CXA-10.

The study will be performed in approximately 50 study centers across the United States and the United Kingdom, which participated in CXA-10-301. Approximately 96 subjects who completed treatment in CXA-10-301 will be eligible to participate in this OLE study, after completing all Visit 9 (Day 1 and Day 2) assessments in CXA-10-301.

Study participation for each subject will last up to approximately 6.5 months. The study will consist of a 6 month open-label treatment period and require 5 clinic visits and 1 telephone visit, including the Baseline Visit completed simultaneously with Visit 9 CXA-10-301, plus a follow-up visit approximately 2 weeks following the last dose of CXA-10.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE PAH
Intervention  ICMJE Drug: CXA-10
(10-nitro-9(E)-octadec-9enoic acid)
Study Arms  ICMJE Experimental: 150mg CXA-10
Once daily dosing of 150mg CXA-10 in the morning
Intervention: Drug: CXA-10
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: August 24, 2020)
Original Estimated Enrollment  ICMJE
 (submitted: August 8, 2019)
Actual Study Completion Date  ICMJE August 12, 2020
Actual Primary Completion Date August 12, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Evidence of a personally signed and dated informed consent document indicating subject has been informed of all pertinent aspects of the study prior to initiation of any study-required procedures.
  2. Is willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
  3. Has completed the CXA-10-301 study and demonstrated compliance with study medication administration and study requirements.
  4. If receiving simvastatin-containing products: simvastatin (Zocor), Vytorin, or any other combination therapy containing simvastatin, simvastatin dose does not exceed 20 mg/day.
  5. Currently receiving no more than three of the following previously approved PAH therapies: phosphodiesterase type 5 (PDE-5) inhibitors, endothelin receptor antagonists (ERA), soluble guanylate cyclase (sGC) stimulator, prostanoids, prostacyclin receptor agonists.
  6. Women of childbearing potential and males with partners of childbearing potential must agree to use a reliable method of contraception while taking study medication.

Exclusion Criteria:

  1. Severe hypotension defined by systolic blood pressure <90 mmHg from sitting blood pressure measurement at Baseline.
  2. Hypertensive defined by >160 mmHg systolic or >110 mmHg diastolic from sitting blood pressure measurement at Baseline.
  3. QTcF on supine ECGs at Baseline (Visit 1) of >500 msec.
  4. Acute myocardial infarction or acute coronary syndrome (ST-Elevation Myocardial Infarction [STEMI], Non STEMI [NSTEMI] and or unstable angina) within the last 90 days prior to Baseline.
  5. Recent cerebrovascular accident/transient ischemic attack (CVA/TIA) within the last 90 days prior to Baseline.
  6. Recent hospitalization for left heart failure within the last 90 days prior to Baseline.
  7. Clinically significant aortic or mitral valve disease defined as greater than mild regurgitation or mild stenosis; pericardial constriction; restrictive or constrictive cardiomyopathy; left ventricular dysfunction (LVEF < 50%); left ventricular outflow obstruction; symptomatic coronary artery disease; autonomic hypotension; or fluid depletion, in the opinion of the investigator.
  8. Chronic atrial fibrillation and life-threatening cardiac arrhythmias.
  9. Personal or family history of congenital prolonged QTc syndrome or sudden unexpected death due to a cardiac reason.
  10. Clinically significant anemia in the opinion of the investigator that precludes enrollment into this study, or Hb <9 gm/dl.
  11. Severe hepatic impairment (Child-Pugh class C with or without cirrhosis) at Baseline or active chronic hepatitis.
  12. Received intravenous inotropes within 2 weeks prior to Baseline (e.g. dopamine, dobutamine).
  13. History of angina pectoris or other condition that was treated with long or short acting nitrates <12 weeks of Baseline.
  14. History of herbal or natural medication use (including fish oil) within 2 weeks or 5 half-lives, whichever is longer, prior to Baseline.
  15. Received prednisone at doses > 15 mg/ day or changes in immunosuppressive medications <12 weeks prior to Baseline.
  16. Currently taking a drug that may affect the assay measurement of serum creatinine (e.g. cimetidine, Bactrim, Pyridium). A list is provided in Appendix H.

21. Newly prescribed drug or increased dose of an existing drug that is known to prolong the QTc interval and has been associated with Torsades de Pointes (TdP) identified in the CredibleMeds.org website list as known risk (KR) of TdP.

Note: Stable doses of drugs classified as conditional risk (CR) of TdP or possible risk (PR) of TdP are permitted (i.e., subject has received the same dose and regimen for at least 30 days prior to Baseline with no anticipated changes to the dose or regimen during the course of the study).

22. Currently taking dimethyl fumarate (Tecfidera™).

23. Any of the following laboratories abnormal and unresolved in CXA-10-301:

  1. Absolute lymphocyte counts < 0.5 x 109 cells/L.
  2. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3.0X upper limit of normal (ULN), alkaline phosphatase (AP) > 2X ULN of liver origin, and total bilirubin >2X ULN. If all liver function tests (LFTs) are within normal limits (WNL) and total bilirubin is elevated, examination of direct and indirect bilirubin may be conducted to evaluate for Rotor's/Gilbert's Syndrome. Subjects with Rotor's/Gilbert's Syndrome may be enrolled.
  3. eGFR < 30 mL/min/1.73 m2 (estimated by Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] Creatinine/Cystatin C 2012 algorithm) at Baseline.

    24. Females who are pregnant or breastfeeding, or who are trying to conceive. 25. Recent (within 1 year) history of abusing alcohol or illicit drugs. 26. History of any primary malignancy, including a history of melanoma or suspicious undiagnosed skin lesions, or other malignancies (such as thyroid or testicular) that have been curatively treated and with no evidence of disease for at least 3 years or prostate cancer who is not currently or expected, during the study, to undergo radiation therapy, chemotherapy, and/or surgical intervention, or to initiate hormonal treatment.

    Exception: subjects with history of basal cell or squamous cell carcinomas of the skin or cervical carcinoma in situ are eligible for enrollment.

    27. Cardiovascular, liver, renal, hematologic, gastrointestinal, immunologic, endocrine, metabolic, central nervous system or psychiatric disease that, in the opinion of the investigator, may adversely affect the safety of the subject and/or efficacy of the investigational product or severely limit the lifespan of the subject other than the condition being studied.

    28. Clinically significant hyperthyroidism or hypothyroidism not adequately treated.

    29. Any other condition and/or situation that causes the Investigator to deem a subject unsuitable for the study (e.g., due to expected study medication non- compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures).

    30. Known hypersensitivity to CXA-10, the metabolites, or formulation excipients.

    31. Treatment with any investigational drug (other than CXA-10) or device within 30 days or 5 half-lives (whichever is longer) prior to Baseline (this includes investigational formulations of marketed products, inhaled and topical drugs), or plans to participate in an investigational drug or device study at any time during this study.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United Kingdom,   United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT04053543
Other Study ID Numbers  ICMJE CXA-10-2302
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Current Responsible Party Complexa, Inc.
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Complexa, Inc.
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE
  • Medpace, Inc.
  • Innovative Analytics
  • Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Investigators  ICMJE
Study Director: Theo Danoff, MD Complexa, Inc.
PRS Account Complexa, Inc.
Verification Date August 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP